Posters Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT034) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors MaaT Pharmamars 19, 2024
Posters Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe MaaT Pharmadécembre 11, 2023
Posters A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating The Efficacy And Safety Of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy In Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: the PHOEBUS trial MaaT Pharmadécembre 11, 2023
Posters Evaluation of a new co-cultured Microbiome Ecosystem Therapy candidate (MaaT03X) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors MaaT Pharmanovembre 3, 2023
Posters Robust Machine Learning (ML) approach for Screening Microbiome Ecosystem Therapies (MET) Drug Candidates in combination with Immune Checkpoint Inhibitors MaaT Pharmanovembre 3, 2023
Posters Benchmarking of shotgun metagenomics analysis results obtained with state-of-the-art optimized pipelines on simulated gut microbiome samples MaaT Pharmajuillet 25, 2023
Posters Restoration of gut microbiota diversity with oral pooled fecal microbiotherapy in acute myeloid leukemia patients after intensive chemotherapy: the phase 1b CIMON trial MaaT Pharmadécembre 11, 2022
Posters Development of a culture manufacturing process preserving the profile of gut microbiota for therapeutic purposes MaaT Pharmanovembre 13, 2022
Posters Pooling of faecal material results in standardized and high-richness microbiotherapy products MaaT013 and MaaT033 MaaT Pharmanovembre 13, 2022
Posters Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program MaaT Pharmanovembre 13, 2022
